IPHA - Innate Pharma S.A. Debt to Book Capitalization Ratio

The price action of Innate Pharma S.A. (IPHA) on the GURU.Markets platform, which currently stands at 0.00, reflects the dynamics of a business implementing AI and robotics for antibody creation. However, geopolitical fragmentation is hindering global testing and the supply of bio-resources. The company's growth relies on a strategic alliance with leading oncology centers, enabling the funding of scientific research without the need for merger and acquisition deals.

IPHA Innate Pharma S.A.: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Innate Pharma SA (IPHA)

- price and consensus price forecast:

Stock Price Innate Pharma S.A.|IPHA - Consensus Target

- market capitalization data:

Market Value Innate Pharma S.A|IPHA - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Innate Pharma|IPHA - Company Book Value|Market Value to Book Value Ratio innate-pharma.com|IPHA - Company Assets

- debt and liquidity data:

Total Debt to Capital Innate Pharma S.A.|IPHA - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Innate Pharma, S.A.|IPHA - Company Cumulative Debt|Debt to Book Value Innate Pharma S.A

Analysis of all company metrics:IPHA, Innate Pharma S.A.

This metric determines the proportion of borrowed funds relative to the total value of assets minus liabilities, measuring the business's degree of financial autonomy. By analyzing the level of debt concentration within the balance sheet capitalization, an investor assesses the risk of credit pressure, which is critically important for Innate Pharma S.A. (IPHA), whose stability is supported by strategic alliances with big pharma and the retention of a unique staff of NK-cell researchers.

Competitors of Innate Pharma S.A.